Yungjin Pharm introduces D-Pharm's new stroke medication

Published: 2006-10-24 06:59:00

Updated: 2006-10-24 06:59:00

Yungjin Pharm said on October 20 it had concluded an exclusive licensing agreement with D-Pharm, an Israel based drug company, to introduce D-Pharm's proprietary ethical agent (DP-b99) for the treatment of acute stroke.

DP-b99 is a unique neuroprotective drug that addresses the array of damagi...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK